Oral efficacy of a diselenide compound loaded in nanostructured lipid carriers in a murine model of visceral leishmaniasis

Leishmaniasis urgently needs new oral treatments, as it is one of the most important neglected tropical diseases that affects people with poor resources. The drug discovery pipeline for oral administration currently discards entities with poor aqueous solubility and permeability (class IV compounds...

Descripción completa

Detalles Bibliográficos
Autores: Etxebeste-Mitxeltorena, M. (Mikel)|||/items/ed41b569-69ef-41f9-805b-e0b9b1e49191, Moreno-Amatria, E. (Esther)|||/items/9dcce7d3-851e-4ffb-9cd0-2f07c8599f4f, Carvalheiro, M. (Manuela)|||/items/84f57a69-92e6-41c5-a3f8-e6e4af08a060, Calvo-Bacaicoa, A. (Alba)|||/items/8557046e-51a2-45a9-b289-9b6e0b1648d3, Navarro-Blasco, I. (Iñigo)|||/items/733b109b-1074-49e9-8952-70ec6928cc54, Gonzalez-Peñas, E. (Elena)|||/items/0e4b9ed7-4224-4664-a4f1-c6403a8c833f, Alvarez-Galindo, J.I. (José Ignacio)|||/items/c88ef755-513c-4ff3-bbff-44aadbf32204, Plano-Amatriain, D. (Daniel)|||/items/238881e4-7d5e-4598-924d-4392e3b7e02e, Irache-Garreta, J.M. (Juan Manuel)|||/items/c7cbbe9e-faeb-47e1-b7e8-2d956ca50173, Almeida, A.J. (Antonio J.)|||/items/bc31603c-5436-4a19-99ab-3ec476e07f2f, Sanmartin-Grijalba, C. (Carmen)|||/items/d36bd105-ab64-427d-9745-5812cf5e7af7, Espuelas, S. (Socorro)|||/items/b57c05de-0bc4-4fcf-ae1e-c9b2fb92964c
Tipo de recurso: artículo
Fecha de publicación:2021
País:España
Institución:Universidad de Navarra
Repositorio:Dadun. Depósito Académico Digital de la Universidad de Navarra
Idioma:inglés
OAI Identifier:oai:dadun.unav.edu:10171/62944
Acceso en línea:https://hdl.handle.net/10171/62944
Access Level:acceso abierto
Palabra clave:Diselenide
Nanostructured lipid carriers
Visceral leishmanisis
L. infantum
Oral treatment
Descripción
Sumario:Leishmaniasis urgently needs new oral treatments, as it is one of the most important neglected tropical diseases that affects people with poor resources. The drug discovery pipeline for oral administration currently discards entities with poor aqueous solubility and permeability (class IV compounds in the Biopharmaceutical Classification System, BCS) such as the diselenide 2m, a trypanothione reductase (TR) inhibitor. This work was assisted by glyceryl palmitostearate and diethylene glycol monoethyl ether-based nanostructured lipid carriers (NLC) to render 2m bioavailable and effective after its oral administration. The loading of 2m in NLC drastically enhanced its intestinal permeability and provided plasmatic levels higher than its effective concentration (IC50). In L. infantum-infected BALB/c mice, 2m-NLC reduced the parasite burden in the spleen, liver, and bone marrow by at least 95% after 5 doses, demonstrating similar efficacy as intravenous Fungizone. Overall, compound 2m and its formulation merit further investigation as an oral treatment for visceral leishmaniasis.